VEGFA and Genetic thrombotic microangiopathy: This may induce a renal vascular injury phenotype similar to that of other VEGF inhibitors such as sunitinib, sorafenib, pazopanib, and axitinib, for which thrombotic microangiopathy ADR has been well described [15,32].